[Psychiatry and mental health in Morocco].

D. Moussaoui

DOI: https://doi.org/10.1016/S0001-4079(19)33013-4

2007-04-01

Abstract:

What problem does this paper attempt to address?

Structural defects of T-even bacteriophages.

Donald J. Cummings,N. Couse,Gerald L. Forrest

DOI: https://doi.org/10.1016/S0065-3527(08)60020-2

Advances in Virus Research

Abstract:
Differential effects of iron chelators on iron burden and long-term morbidity and mortality outcomes in a large cohort of transfusion-dependent β-thalassemia patients who remained on the same monotherapy over 10 years

Khaled M Musallam,Susanna Barella,Raffaella Origa,Giovanni Battista Ferrero,Roberto Lisi,Annamaria Pasanisi,Filomena Longo,Barbara Gianesin,Gian Luca Forni,Webthal® project

DOI: https://doi.org/10.1016/j.bcmd.2024.102859

Abstract:We conducted a retrospective cohort study on 663 transfusion-dependent β-thalassemia patients receiving the same iron chelation monotherapy with deferoxamine, deferiprone, or deferasirox for up to 10 years (median age 31.8 years, 49.9 % females). Patients on all three iron chelators had a steady and significant decline in serum ferritin over the 10 years (median deferoxamine: -170.7 ng/mL, P = 0.049, deferiprone: -236.7 ng/mL, P = 0.001; deferasirox: -323.7 ng/mL, P < 0.001) yet had no significant change in liver iron concentration or cardiac T2*; while noting that patients generally had low hepatic and cardiac iron levels at study start. Median absolute, relative, and normalized changes were generally comparable between the three iron chelators. Patients receiving deferasirox had the highest morbidity and mortality-free survival probability among the three chelators, although the difference was only statistically significant when compared with deferoxamine (P = 0.037). On multivariate Cox regression analysis, there was no significant association between iron chelator type and the composite outcome of morbidity or mortality. In a real-world setting, there is comparable long-term iron chelation effectiveness between the three available iron chelators for patients with mild-to-moderate iron overload.
Pulmonary function in patients with transfusion-dependent thalassemia and its associations with iron overload

Kate C Chan,Chun T Au,Alex W K Leung,Albert M Li,Chi-Kong Li,Matthew M T Wong,Carol S T Li,Hang L Cheung,Philip Fan,Siu C Ling,Rever C H Li,S Y Ha

DOI: https://doi.org/10.1038/s41598-023-30784-9

2023-03-04

Abstract:In patients with transfusion-dependent thalassemia (TDT), pulmonary function impairment has been reported but data are conflicting. Moreover, it remains unclear whether pulmonary dysfunction is associated with iron overload. This study aimed to evaluate the pulmonary function in patients with TDT and to investigate the associations between pulmonary dysfunction and iron overload. It was a retrospective observational study. 101 patients with TDT were recruited for lung function tests. The most recent ferritin levels (pmol/L) and the magnetic resonance imaging (MRI) measurements of the myocardial and liver iron status, as measured by heart and liver T2* relaxation time (millisecond, ms) respectively, were retrieved from the computerized medical records. Only data within 12 months from the lung function measurement were included in the analysis. The serum ferritin, and the cardiac and liver T2* relaxation time were the surrogate indexes of body iron content. The threshold of abnormality in lung function was defined as under 80% of the predicted value. 101 subjects were recruited with a mean age of 25.1 years (standard deviation (SD) 7.9 years). Thirty-eight (38%) and five (5%) demonstrated restrictive and obstructive lung function deficits, respectively. A weak correlation of FVC %Predicted and TLC %Predicted with MRI myocardial T2* relaxation time (rho = 0.32, p = 0.03 and rho = 0.33, p = 0.03 respectively) was observed. By logistic regression, MRI cardiac T2* relaxation time was negatively associated with restrictive lung function deficit (B - 0.06; SE 0.03; Odds ratio 0.94; 95% confidence interval (CI) 0.89-0.99; p = 0.023) after adjusting for age, sex and body mass index. Restrictive pulmonary function deficit was commonly observed in patients with TDT, and the severity potentially correlates with myocardial iron content. Monitoring of lung function in this group of patients, particularly for those with iron overload, is important.
Higher hemoglobin is better in thalassemia

Thomas D Coates,Thomas D. Coates

DOI: https://doi.org/10.1182/blood.2023023294

IF: 20.3

2024-03-08

Blood

Abstract:In this issue of Blood , Musallam, Forni, and colleagues show that survival in transfusion dependent β-thalassemia (TDT) is measurably better in patients whose pretransfusion hemoglobin levels are maintained >10.5 g/dL, at the upper end of the currently recommended treatment range. 1 In this landmark study, the 10-year survival of a group of 779 patients with TDT of median age 33.1 years (range 18.1-61 years) increased monotonically from 91% to 100% in 5 categories marked by median pretransfusion hemoglobin levels that increased from <9.0 to ≥10.5 g/dL in 0.5-g/dL increments. Of note, 88% of the thalassemia-related deaths were in groups with a median hemoglobin <10 g/dL and 70% were from cardiovascular disease. When the data were stratified by ferritin, the association with hemoglobin level groups was only significant for ferritin <1000 ng/mL, consistent with an effect of anemia on survival separate from that of iron overload.

hematology
Clinical Burden and Healthcare Resource Utilization Associated With Managing Transfusion-dependent β -Thalassemia in England

Chuka Udeze,Nelly F. Ly,Fiona C. Ingleby,Sophia D. Fleming,Sarah C. Conner,Jo Howard,Nanxin Li,Farrukh Shah

DOI: https://doi.org/10.1016/j.clinthera.2024.09.024

IF: 3.637

2024-11-03

Clinical Therapeutics

Abstract:Purpose Patients with transfusion-dependent β -thalassemia (TDT) have reduced levels of β -globin, leading to ineffective erythropoiesis and iron overload. Patients with TDT depend on regular red blood cell transfusions (RBCTs) and iron chelation therapy for survival and management of disease- and treatment-related clinical complications. This study describes the clinical and economic burden in patients with TDT in England. Methods This longitudinal, retrospective study linked the Clinical Practice Research Datalink (CPRD) database with secondary care data from the Hospital Episode Statistics database to identify patients with a diagnosis of β -thalassemia between July 1, 2008, and June 30, 2018. Included patients had a diagnosis of β -thalassemia prior to the index date, ≥8 RBCTs per year for ≥2 consecutive years, and ≥1 year of follow-up data available from the index date. Each eligible patient was exact matched with up to 5 controls in the CPRD. Proportions of deaths and rates of mortality, acute and chronic complications, and healthcare resource utilization (HCRU) were calculated during the follow-up period. Findings Of 11,359 identified patients with β -thalassemia, 237 patients with TDT met the eligibility criteria and were matched with 1184 controls. The mean age at the index date was approximately 25 years in the patient and control groups. The proportion of deaths (7.17% vs 1.18%; P < 0.05) and mortality rate (1.19 deaths per 100 person-years vs 0.20 deaths per 100 person-years) were higher among patients with TDT compared to controls. Endocrine complications and bone disorders were the most prevalent complications among patients with TDT (58.23%) and included osteoporosis (29.11%), diabetes mellitus (28.27%), and hypopituitarism (28.27%). Patients with TDT had a mean of 13.62 RBCTs per patient per year (PPPY). HCRU was substantially higher among patients with TDT, wherein patients with TDT had higher rates of prescriptions recorded in primary care (24.09 vs 8.61 PPPY), outpatient visits (16.69 vs 1.31 PPPY), and inpatient hospitalizations (17.41 vs 0.24 PPPY) than controls. Inpatient hospitalizations were primarily <1 day, with 16.62 events PPPY lasting <1 day and 0.79 events PPPY lasting ≥1 day. Patients with TDT aged ≥18 years had increased rates of mortality, clinical complications, and HCRU than those aged <18 years. Implications Patients with TDT in England have higher mortality than matched controls, substantial disease-related clinical complications, and substantial HCRU. High mortality and clinical complications highlight the need for additional innovative therapies for TDT.

pharmacology & pharmacy
POSTURAL BEHAVIOUR OF TERM SGA AND AGA NEWBORN INFANTS

V. H. Kranen-Mastenbroek,K. Folmer,H. Kingma,H. Caberg,C. Blanco,T. Hasaart,J. Vles

DOI: https://doi.org/10.1111/j.1469-8749.1993.tb11682.x

1993-06-01

Developmental Medicine & Child Neurology

Abstract:The authors studied the body posture at rest of 15 healthy term infants with birthweights appropriate for gestational age (AGA) and 15 infants who were small for gestational age (SGA). In both groups, there was wide inter‐individual variability in pos:ural behaviour. Apart from a preference for a position with all limbs in abduction between I and 90°, independent of the degree of flexion or extension and internal/external rotation, no dominant preference posture could be seen for either group. The SGA infants showed a more flexed position of the arms, ccrnpared with the AGA group. One of the factors contributing to this difference might be the influence of intrauterine malnutrition on the development of the central nervous system.
Management of Iron Overload in Beta-Thalassemia Patients: Clinical Practice Update Based on Case Series

Valeria Maria Pinto,Gian Luca Forni

DOI: https://doi.org/10.3390/ijms21228771

2020-11-20

Abstract:Thalassemia syndromes are characterized by the inability to produce normal hemoglobin. Ineffective erythropoiesis and red cell transfusions are sources of excess iron that the human organism is unable to remove. Iron that is not saturated by transferrin is a toxic agent that, in transfusion-dependent patients, leads to death from iron-induced cardiomyopathy in the second decade of life. The availability of effective iron chelators, advances in the understanding of the mechanism of iron toxicity and overloading, and the availability of noninvasive methods to monitor iron loading and unloading in the liver, heart, and pancreas have all significantly increased the survival of patients with thalassemia. Prolonged exposure to iron toxicity is involved in the development of endocrinopathy, osteoporosis, cirrhosis, renal failure, and malignant transformation. Now that survival has been dramatically improved, the challenge of iron chelation therapy is to prevent complications. The time has come to consider that the primary goal of chelation therapy is to avoid 24-h exposure to toxic iron and maintain body iron levels within the normal range, avoiding possible chelation-related damage. It is very important to minimize irreversible organ damage to prevent malignant transformation before complications set in and make patients ineligible for current and future curative therapies. In this clinical case-based review, we highlight particular aspects of the management of iron overload in patients with beta-thalassemia syndromes, focusing on our own experience in treating such patients. We review the pathophysiology of iron overload and the different ways to assess, quantify, and monitor it. We also discuss chelation strategies that can be used with currently available chelators, balancing the need to keep non-transferrin-bound iron levels to a minimum (zero) 24 h a day, 7 days a week and the risk of over-chelation.
Oxidative Stress and Antioxidant Status in Adult Patients with Transfusion-Dependent Thalassemia: Correlation with Demographic, Laboratory, and Clinical Biomarkers

Antonella Meloni,Laura Pistoia,Anna Spasiano,Antonella Cossu,Tommaso Casini,Antonella Massa,Sergio Bagnato,Maria Caterina Putti,Silvia Maffei,Vincenzo Positano,Alessia Pepe,Filippo Cademartiri,Cristina Vassalle

DOI: https://doi.org/10.3390/antiox13040446

IF: 7.675

2024-04-11

Antioxidants

Abstract:Iron overload in beta transfusion-dependent thalassemia (β-TDT) may provoke oxidative stress and reduction of the antioxidant defenses, with serious consequences for the disease course and complications. The present study evaluated the oxidant/antioxidant status of β-TDT patients and its correlation with demographic, clinical, laboratory, and instrumental biomarkers. The OXY-adsorbent assay and the d-ROMs (Diacron, Grosseto, Italy) were evaluated in 58 β-TDT patients (mean age: 37.55 ± 7.83 years, 28 females) enrolled in the Extension-Myocardial Iron Overload in Thalassemia Network. Iron overload was quantified with R2* magnetic resonance imaging. Mean OXY was 323.75 ± 113.19 μmol HClO/mL and 39 (67.2%) patients showed a decreased OXY-Adsorbent level (<350 μmol HClO/mL), of whom 22 (37.9%) showed severely reduced levels. Mean d-ROMs was 305.12 ± 62.19 UA; 12 (20.7%) patients showed oxidative stress, and 4 (6.9%) elevated oxidative stress. OXY showed a significant negative correlation with global and segmental cardiac iron levels. D-ROMs levels significantly correlated with markers of cardiovascular risk (aging, glycemia, and N-terminal pro-B-type natriuretic peptide). Antioxidant depletion is frequent in β-TDT patients, where OXY might serve as additive biomarker to assess heart iron status, whereas the d-ROMs might be helpful to assess the cardiovascular risk burden.

biochemistry & molecular biology,chemistry, medicinal,food science & technology
Overall and complication-free survival in a large cohort of patients with β-thalassemia major followed over 50 years

Gian Luca Forni,Barbara Gianesin,Khaled M Musallam,Filomena Longo,Rosamaria Rosso,Roberto Lisi,Maria Rita Gamberini,Valeria Maria Pinto,Giovanna Graziadei,Angelantonio Vitucci,Federico Bonetti,Pellegrino Musto,Antonio Piga,Maria Domenica Cappellini,Caterina Borgna-Pignatti,Webthal® project

DOI: https://doi.org/10.1002/ajh.26798

Abstract:We report data on survival and complications for a longitudinal cohort of 709 transfusion-dependent β-thalassemia major patients (51.1% males) born between 1970 and 1997 and followed through 2020 at seven major centers in Italy. Overall survival probability at 30 years was 83.6% (95%CI: 78.5-89.1) in the oldest birth cohort (1970-1974) compared with 93.3% (95%CI: 88.6-98.3) in the youngest birth cohort (1985-1997) (p = 0.073). Females showed better survival than males (p = 0.022). There were a total of 93 deaths at a median age of 23.2 years with the most frequent disease-related causes being heart disease (n = 53), bone marrow transplant (BMT) complication (n = 10), infection (n = 8), liver disease (n = 4), cancer (n = 3), thromboembolism (n = 2) and severe anemia (n = 1). There was a steady decline in the number of deaths due to heart disease from the year 2000 onwards and no death from BMT was observed after the year 2010. A progressive decrease in the median age of BMT was observed in younger birth cohorts (p < 0.001). A total of 480 (67.7%) patients developed ≥1 complication. Patients in younger birth cohorts demonstrated better complication-free survival (p < 0.001) which was comparable between sexes (p = 0.230). Independent risk factors for death in multivariate analysis included heart disease (HR: 4.63, 95%CI: 1.78-12.1, p = 0.002), serum ferritin >1000 ng/mL (HR: 15.5, 95%CI: 3.52-68.2, p < 0.001), male sex (HR: 2.75, 95%CI: 0.89-8.45, p = 0.078), and splenectomy (HR: 6.97, 95%CI: 0.90-54.0, p < 0.063). Survival in patients with β-thalassemia major continues to improve with adequate access to care, best practice sharing, continued research, and collaboration between centers.
Progression of liver fibrosis can be controlled by adequate chelation in transfusion-dependent thalassemia (TDT)

D Maira,E Cassinerio,A Marcon,M Mancarella,M Fraquelli,P Pedrotti,M D Cappellini

DOI: https://doi.org/10.1007/s00277-017-3120-9

Abstract:A substantial proportion of patients with transfusion-dependent beta-thalassemia major suffer from chronic liver disease. Iron overload resulting from repeated transfusions and HCV infection has been implicated in the development of liver fibrosis. Hepatic siderosis and fibrosis were assessed in 99 transfusion-dependent thalassemia (TDT) patients using transient elastography (TE) and liver iron concentration (LIC) assessed by T2*MRI at baseline and after 4 years. Data were analyzed retrospectively. At baseline, the overall mean liver stiffness measurement (LSM) was 7.4 ± 3.2 kPa and the mean LIC was 4.81 ± 3.82 mg/g dw (n = 99). Data available at 4 ± 1.5 years showed a significant reduction in LSM (6.6 ± 3.2 kPa, p 0.017) and hepatic siderosis measured by LIC (3.65 ± 3.45 mg/g dw, p 0.001). This result was confirmed when considering patients with iron overload at the time of the first measurement (n = 41) and subjects treated with a stable dose of deferasirox over the entire period of observation (n = 39). A reduction of LSM, yet not statistically significant, was achieved in patients on combined deferoxamine + deferiprone, while the group on deferoxamine (n = 11) remained stable over time. HCV-RNA positivity was found in 33 patients at T0, 20 of which were treated during the observation period. Patients who underwent anti-HCV therapy showed a more evident reduction in LSM (9 ± 3 vs 7 ± 3.1 kPa, p 0.016). Adequate chelation therapy is mandatory in order to prevent liver disease progression in TDT. Patients could benefit from regular non-invasive assessment of liver fibrosis by TE to indirectly monitor treatment adequacy and therapeutic compliance.
Thalassemia major between liver and heart: Where we are now

Carlo Dessì,GiovanBattista Leoni,Paolo Moi,Fabrice Danjou,Ilenia Follesa,Maria Loreta Foschini,Maddalena Morittu,Antonietta Zappu,Elisabetta Defraia,Patrizio Bina,Andrea Cunico,Alberto Civolani,Rosa Anna Podda,Raffaella Origa

DOI: https://doi.org/10.1016/j.bcmd.2015.03.010

Abstract:The aim of the study was to assess the current state in terms of liver and heart iron overload as well as of liver and heart related morbidity and mortality in a large cohort of thalassemia patients. Myocardial iron loading was present in 28.9% patients, which was severe in 3.2%. Liver iron was normal in 9.3% and severe in 15%. The rate of cardiac deaths started to decrease between 2000 and 2003 and dropped significantly afterwards. The prescription of combination therapy soon after the hospital admission for decompensated heart failure was associated with a decrease in the short-term mortality. In 111 adult patients who underwent liver elastometry, 14 HCVRNA positive subjects and 2 HCVRNA negative, had stiffness values suggestive of cirrhosis. No cases of hepatocarcinoma were reported. Liver "iron free foci" occurred in a HCV negative patient and the occurrence of a malignant epithelioid hemangioendothelioma led to liver transplantation in another. The study suggests that a subset of patients continues to develop progressive hemosiderosis that may lead to cardiac disease and death. Beyond its key role in preventing myocardial iron overload, liver iron chelation is essential for hampering the onset of hepatic tumors, which may not be limited to hepatocarcinoma.
Magnetic Resonance Evaluation of Tissue Iron Deposition and Cardiac Function in Adult Regularly Transfused Thalassemia Intermedia Compared with Thalassemia Major Patients

Antonella Meloni,Laura Pistoia,Paolo Ricchi,Filomena Longo,Valerio Cecinati,Francesco Sorrentino,Zelia Borsellino,Sergio Bagnato,Vincenza Rossi,Priscilla Fina,Ada Riva,Stefania Renne,Giuseppe Peritore,Vincenzo Positano,Filippo Cademartiri

DOI: https://doi.org/10.3390/jcm13164791

2024-08-14

Abstract:Objectives: This multicenter, retrospective, population-based, matched-cohort study compared clinical characteristics and magnetic resonance imaging (MRI) findings, including hepatic, pancreatic, and cardiac iron levels and cardiac function, between 135 adult regularly transfused thalassemia intermedia (TI) patients (44.73 ± 12.16 years, 77 females) and 135 age- and sex-matched thalassemia major (TM) patients (43.35 ± 9.83 years, 77 females), enrolled in the Extension-Myocardial Iron Overload in Thalassemia Network. Methods: The MRI protocol included the quantification of hepatic, pancreatic, and cardiac iron levels (R2* technique), the assessment of biventricular function parameters (cine images), and the detection of replacement myocardial fibrosis (late gadolinium enhancement technique). Results: Age, sex, frequency of splenectomy and chelation, and serum ferritin levels were not significantly different (p > 0.05) between the two groups, but TI patients started regular transfusions significantly later (p < 0.0001) and showed significantly lower pre-transfusion hemoglobin levels (p = 0.005). No difference was found in hepatic iron levels (p = 0.853). TI patients exhibited significantly lower pancreatic R2* values (p < 0.0001), also correcting for the duration of regular transfusions, and significantly lower cardiac R2* values (p < 0.0001). In the receiver operating characteristic analysis, pancreatic iron was the strongest discriminator between the two diseases. Left and right ventricular end-diastolic volume indexes were significantly higher in TI than in TM patients (p = 0.003 and p = 0.046, respectively), but the correction for the duration of regular transfusions removed the disease-specific differences (p > 0.05). Left ventricular (LV) mass index was significantly higher in TI (p = 0.049), while no difference (p > 0.05) was found in biventricular ejection fractions and replacement myocardial fibrosis. Conclusions: TI patients showed lower pancreatic and cardiac iron burden and more pronounced LV hypertrophy. These differences could not be explained by the different duration of the transfusional regimen.
Management of iron overload in hemoglobinopathies: what is the appropriate target iron level?

Thomas D Coates,Susan Carson,John C Wood,Vasilios Berdoukas,Thomas D. Coates,John C. Wood

DOI: https://doi.org/10.1111/nyas.13060

IF: 6.499

2016-03-01

Annals of the New York Academy of Sciences

Abstract:Patients with thalassemia become iron overloaded from increased absorption of iron, ineffective erythropoiesis, and chronic transfusion. Before effective iron chelation became available, thalassemia major patients died of iron-related cardiac failure in the second decade of life. Initial treatment goals for chelation therapy were aimed at levels of ferritin and liver iron concentrations associated with prevention of adverse cardiac outcomes and avoidance of chelator toxicity. Cardiac deaths were greatly reduced and survival was much longer. Epidemiological data from the general population draw clear associations between increased transferrin saturation (and, by inference, labile iron) and early death, diabetes, and malignant transformation. The rate of cancers now seems to be significantly higher in thalassemia than in the general population. Reduction in iron can reverse many of these complications and reduce the risk of malignancy. As toxicity can result from prolonged exposure to even low levels of excess iron, and survival in thalassemia patients is now many decades, it would seem prudent to refocus attention on prevention of long-term complications of iron overload and to maintain labile iron and total body iron levels within a normal range, if expertise and resources are available to avoid complications of overtreatment.

multidisciplinary sciences
Liver steatosis in patients with transfusion‐dependent thalassaemia

Paolo Ricchi,Laura Pistoia,Vincenzo Positano,Anna Spasiano,Tommaso Casini,Maria Caterina Putti,Zelia Borsellino,Antonella Cossu,Giuseppe Messina,Petra Keilberg,Carmina Fatigati,Silvia Costantini,Stefania Renne,Giuseppe Peritore,Filippo Cademartiri,Antonella Meloni

DOI: https://doi.org/10.1111/bjh.19496

2024-05-01

British Journal of Haematology

Abstract:Hepatic fat fraction is significantly higher in transfusion‐dependent thalassaemia (TDT) patients than in healthy subjects. In TDT, liver steatosis is a frequent finding, associated with iron overload, increased body weight and hepatitis C virus (HCV) infection, and conveying an increased risk for the alterations of glucose metabolism. Summary We evaluated the prevalence and the clinical associations of liver steatosis (LS) in patients with transfusion‐dependent thalassaemia (TDT). We considered 301 TDT patients (177 females, median age = 40.61 years) enrolled in the Extension‐Myocardial Iron Overload in Thalassaemia Network, and 25 healthy subjects. Magnetic resonance imaging was used to quantify iron overload and hepatic fat fraction (FF) by T2* technique and cardiac function by cine images. The glucose metabolism was assessed by the oral glucose tolerance test (OGTT). Hepatic FF was significantly higher in TDT patients than in healthy subjects (median value: 1.48% vs. 0.55%; p = 0.013). In TDT, hepatic FF was not associated with age, gender, serum ferritin levels or liver function parameters, but showed a weak inverse correlation with high‐density lipoprotein cholesterol. The 36.4% of TDT patients showed LS (FF >3.7%). Active hepatitis C virus (HCV) infection, increased body mass index and hepatic iron were independent determinants of LS. A hepatic FF >3.53% predicted the presence of an abnormal OGTT. Hepatic FF was not correlated with cardiac iron, biventricular volumes or ejection fractions, but was correlated with left ventricular mass index. In TDT, LS is a frequent finding, associated with iron overload, increased weight and HCV, and conveying an increased risk for the alterations of glucose metabolism.

hematology
Prognostic Role of Multiparametric Cardiac Magnetic Resonance in Neo Transfusion-Dependent Thalassemia

Antonella Meloni,Laura Pistoia,Paolo Ricchi,Aurelio Maggio,Valerio Cecinati,Filomena Longo,Francesco Sorrentino,Zelia Borsellino,Alessandra Salvo,Vincenza Rossi,Emanuele Grassedonio,Gennaro Restaino,Stefania Renne,Riccardo Righi,Vincenzo Positano,Filippo Cademartiri

DOI: https://doi.org/10.3390/jcm13051281

IF: 3.9

2024-02-24

Journal of Clinical Medicine

Abstract:Background: We prospectively evaluated the predictive value of multiparametric cardiac magnetic resonance (CMR) for cardiovascular complications in non-transfusion-dependent β-thalassemia (β-NTDT) patients who started regular transfusions in late childhood/adulthood (neo β-TDT). Methods: We considered 180 patients (38.25 ± 11.24 years; 106 females). CMR was used to quantify cardiac iron overload, biventricular function, and atrial dimensions, and to detect left ventricular (LV) replacement fibrosis. Results: During a mean follow-up of 76.87 ± 41.60 months, 18 (10.0%) cardiovascular events were recorded: 2 heart failures, 13 arrhythmias (10 supraventricular), and 3 cases of pulmonary hypertension. Right ventricular (RV) end-diastolic volume index (EDVI), RV mass index (MI), LV replacement fibrosis, and right atrial (RA) area index emerged as significant univariate prognosticators of cardiovascular complications. The low number of events prevented us from performing a multivariable analysis including all univariable predictors simultaneously. Firstly, a multivariable analysis including the two RV size parameters (mass and volume) was carried out, and only the RV MI was proven to independently predict cardiovascular diseases. Then, a multivariable analysis, including RV MI, RA atrial area, and LV replacement fibrosis, was conducted. In this model, RV MI and LV replacement fibrosis emerged as independent predictors of cardiovascular outcomes (RV MI: hazard ratio (HR) = 1.18; LV replacement fibrosis: HR = 6.26). Conclusions: Our results highlight the importance of CMR in cardiovascular risk stratification.

medicine, general & internal
The effect of iron chelation therapy on overall survival in sickle cell disease and β-thalassemia: A systematic review

Samir K Ballas,Amer M Zeidan,Vu H Duong,Michelle DeVeaux,Matthew M Heeney

DOI: https://doi.org/10.1002/ajh.25103

Abstract:Red blood cell transfusions have become standard of care for the prevention of life-threatening anemia in patients with β-thalassemia and sickle cell disease (SCD). However, frequent transfusions can lead to accumulation of iron that can result in liver cirrhosis, diabetes mellitus, arthritis, arrhythmias, cardiomyopathy, heart failure, and hypogonadotropic hypogonadism. Iron chelation therapy has been shown to reduce serum ferritin levels and liver iron content, but limitations of trial design have prevented any demonstration of improved survival. The objective of this systematic review was to investigate the impact of iron chelation therapy on overall and event-free survival in patients with β-thalassemia and SCD. Eighteen articles discussing survival in β-thalassemia and 3 in SCD were identified. Overall iron chelation therapy resulted in better overall survival, especially if it is instituted early and compliance is maintained. Comparative studies did not show any significant differences between available iron chelation agents, although there is evidence that deferiprone is better tolerated than deferoxamine and that compliance is more readily maintained with the newer oral drugs, deferiprone and deferasirox. Iron chelation therapy, particularly the second-generation oral agents, appears to be associated with improved overall and event-free survival in transfusion-dependent patients with β-thalassemia and patients with SCD.
Iron overload: the Achilles heel of β- thalassemia

Efthymia Vlachaki,Theodora-Maria Venou

DOI: https://doi.org/10.1016/j.tracli.2024.06.001

IF: 2.126

2024-06-08

Transfusion Clinique et Biologique

Abstract:Systematic transfusions coupled with iron chelation therapy have substantially improved the life expectancy of thalassemia patients in developed nations. As the human organism does not have a protective mechanism to remove excess iron, iron overload is a significant concern in thalassemia, leading to organ damage, especially in the heart and liver. Thus, iron chelation therapy is crucial to prevent or reverse organ iron overload. There are three widely used iron chelators, either as monotherapy or in combination. The choice of iron chelator depends on several factors, including local guidelines, drug availability, and the individual clinical scenario. Despite treatment advancements, challenges persist, especially in resource-limited settings, highlighting the need for improved global healthcare access. This review discusses clinical management, current treatments, and future directions for thalassemia, focusing on iron overload and its complications. Furthermore, it underscores the progress in transforming thalassemia into a manageable chronic condition and the potential of novel therapies to further enhance patient outcomes.

immunology,hematology
Skin grafts of the orbit.

L. Farkas,M. Fára

Acta Chirurgiae Plasticae

Abstract:
Private company that took over failing NHS hospital seeks £47.5m to prevent insolvency

N. Hawkes

DOI: https://doi.org/10.1136/bmj.e3862

2012-05-31

British Medical Journal

Abstract:Circle, the private company that won the contract to run Hinchingbrooke Hospital in Cambridgeshire, has launched a new round of funding at a deep discount to the price at which it floated on the alternative investment market (AIM) a year ago. It is seeking to raise an additional £47.5m (€59m; $74m) (£46m after expenses) at a price of 70 p per share, and has received undertakings from existing shareholders representing 75% of the existing capital to vote in favour of the required resolutions at a shareholders’ meeting. The company plans to use the money to pay off an existing loan with a high …
Nasal Schneiderian papillomas: a study of 83 cases.

S. Kristensen,P. Vorre,O. Elbrønd,H. Søgaard

DOI: https://doi.org/10.1111/J.1365-2273.1985.TB01181.X

1985-06-01

Clinical Otolaryngology and Allied Sciences

Abstract:Nasal Schneiderian papillomas are unique lesions involving the mucosa of the nasal cavity and paranasal sinuses. Most often epidermoid in histological appearance, they favour 2 sites: the septum and the lateral wall of the nasal cavity. The medical literature on these tumours contains a plethora of contradictions concerning the nomenclature and no less than 54 separate designations are used. The synonyms are discussed and the term Schneiderian papilloma is proposed as the most suitable alternative. This study includes 83 patients with Schneiderian papillomas in whom the history, clinical and radiological findings, treatment procedures, pathological sections, recurrences, and associated malignancies were analyzed. Histological and clinical features were not helpful in predicting recurrence, but the recurrence rate was related to the treatment modalities; with 17% recurrences using an extranasal approach (lateral rhinotomy) and 59% using intranasal approach with limited excision. Schneiderian papillomas were associated with squamous cell carcinoma in 7 patients. Simultaneous papilloma and carcinoma were demonstrated in 4 patients at presentation (5%) and subsequently developing carcinoma in 3 patients (4%). As recurrences are frequent after inadequate removal and as association with maligancies may occur in both septal and lateral wall papillomas, radical aggressive surgery, thorough histological examination of the entire specimen, and careful follow-up are advocated.

[Psychiatry and mental health in Morocco].

Structural defects of T-even bacteriophages.

Differential effects of iron chelators on iron burden and long-term morbidity and mortality outcomes in a large cohort of transfusion-dependent β-thalassemia patients who remained on the same monotherapy over 10 years

Pulmonary function in patients with transfusion-dependent thalassemia and its associations with iron overload

Higher hemoglobin is better in thalassemia

Clinical Burden and Healthcare Resource Utilization Associated With Managing Transfusion-dependent β -Thalassemia in England

POSTURAL BEHAVIOUR OF TERM SGA AND AGA NEWBORN INFANTS

Management of Iron Overload in Beta-Thalassemia Patients: Clinical Practice Update Based on Case Series

Oxidative Stress and Antioxidant Status in Adult Patients with Transfusion-Dependent Thalassemia: Correlation with Demographic, Laboratory, and Clinical Biomarkers

Overall and complication-free survival in a large cohort of patients with β-thalassemia major followed over 50 years

Progression of liver fibrosis can be controlled by adequate chelation in transfusion-dependent thalassemia (TDT)

Thalassemia major between liver and heart: Where we are now

Magnetic Resonance Evaluation of Tissue Iron Deposition and Cardiac Function in Adult Regularly Transfused Thalassemia Intermedia Compared with Thalassemia Major Patients

Management of iron overload in hemoglobinopathies: what is the appropriate target iron level?

Liver steatosis in patients with transfusion‐dependent thalassaemia

Prognostic Role of Multiparametric Cardiac Magnetic Resonance in Neo Transfusion-Dependent Thalassemia

The effect of iron chelation therapy on overall survival in sickle cell disease and β-thalassemia: A systematic review

Iron overload: the Achilles heel of β- thalassemia

Skin grafts of the orbit.

Private company that took over failing NHS hospital seeks £47.5m to prevent insolvency

Nasal Schneiderian papillomas: a study of 83 cases.